Vulvovaginal Candidiasis - Pipeline Review, H2 2016

Date: September 14, 2016
Pages: 63
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: V8663FCA9F6EN
Leaflet:

Download PDF Leaflet

Vulvovaginal Candidiasis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Vulvovaginal Candidiasis - Pipeline Review, H2 2016’, provides an overview of the Vulvovaginal Candidiasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vulvovaginal Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vulvovaginal Candidiasis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Vulvovaginal Candidiasis
  • The report reviews pipeline therapeutics for Vulvovaginal Candidiasis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Vulvovaginal Candidiasis therapeutics and enlists all their major and minor projects
  • The report assesses Vulvovaginal Candidiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Vulvovaginal Candidiasis
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Vulvovaginal Candidiasis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Vulvovaginal Candidiasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Vulvovaginal Candidiasis Overview
Therapeutics Development
Pipeline Products for Vulvovaginal Candidiasis - Overview
Vulvovaginal Candidiasis - Therapeutics under Development by Companies
Vulvovaginal Candidiasis - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Vulvovaginal Candidiasis - Products under Development by Companies
Vulvovaginal Candidiasis - Companies Involved in Therapeutics Development
Cidara Therapeutics, Inc.
Grupo Ferrer Internacional, S.A.
NovaDigm Therapeutics, Inc.
Scynexis, Inc.
TGV-Laboratories
Viamet Pharmaceuticals, Inc.
Vulvovaginal Candidiasis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(clotrimazole + diclofenac sodium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arasertaconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CD-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MH-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myc-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDV-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDV-3A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCY-078 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOL-463 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-1161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vulvovaginal Candidiasis - Dormant Projects
Vulvovaginal Candidiasis - Discontinued Products
Vulvovaginal Candidiasis - Product Development Milestones
Featured News & Press Releases
Aug 15, 2016: NovaDigm Therapeutics Announces Positive Results from First-ever Antifungal Immunotherapy in a Phase 2a Study in Women with Recurrent Vulvovaginal Candidiasis
Aug 10, 2016: Positive Interim Clinical Results for VT-1161 to be Presented at the Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting
Aug 09, 2016: Cidara Therapeutics Announced Presentations Addressing Vulvovaginal Candidiasis at Upcoming IDSOG Annual Meeting
Aug 08, 2016: SCYNEXIS Reports Second Quarter 2016 Financial Results and Provides Company Update
Jun 09, 2016: Cidara Therapeutics Doses First Patient in Phase 2 Trial of CD101 Topical to Treat Vulvovaginal Candidiasis
Jun 08, 2016: Cidara Therapeutics to Present Data on Lead Antifungal Product Candidate CD101 at Upcoming ASM Microbe 2016
Jun 08, 2016: SCYNEXIS Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors
May 31, 2016: FDA Grants QIDP and Fast Track Designation to CD101 Topical, Cidara Therapeutics Novel Antifungal Product Candidate
Mar 09, 2016: Viamet Reports Positive Results from Interim Analysis of REVIVE Phase 2b Trial of VT-1161 in Recurrent Vulvovaginal Candidiasis
Jan 28, 2016: SCYNEXIS Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections
Jan 11, 2016: Cidara Therapeutics Announces Positive Data from Multiple Dose Phase 1 Clinical Trial of CD101 IV
Dec 01, 2015: SCYNEXIS Initiates Enrollment of the Phase 2 Study of SCY-078 in Vulvovaginal Candidiasis
Jul 29, 2015: Viamet to Present at Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting
Apr 24, 2015: Viamet to Provide Update on VT-1161, Novel Antifungal Program at ECCMID 2015
Feb 12, 2015: Viamet Announces Initiation of REVIVE Phase 2b Study of VT-1161 in Recurrent Vulvovaginal Candidiasis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 63

LIST OF TABLES

Number of Products under Development for Vulvovaginal Candidiasis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Vulvovaginal Candidiasis - Pipeline by Cidara Therapeutics, Inc., H2 2016
Vulvovaginal Candidiasis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2016
Vulvovaginal Candidiasis - Pipeline by NovaDigm Therapeutics, Inc., H2 2016
Vulvovaginal Candidiasis - Pipeline by Scynexis, Inc., H2 2016
Vulvovaginal Candidiasis - Pipeline by TGV-Laboratories, H2 2016
Vulvovaginal Candidiasis - Pipeline by Viamet Pharmaceuticals, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Vulvovaginal Candidiasis - Dormant Projects, H2 2016
Vulvovaginal Candidiasis - Discontinued Products, H2 2016 49

LIST OF FIGURES

Number of Products under Development for Vulvovaginal Candidiasis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Candidiasis - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 151 pages

Ask Your Question

Vulvovaginal Candidiasis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: